Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Share News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,760.00
Bid: 1,760.00
Ask: 1,766.00
Change: -10.00 (-0.56%)
Spread: 6.00 (0.341%)
Open: 1,784.00
High: 1,784.00
Low: 1,756.00
Prev. Close: 1,770.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Restockng drive in China sees Genus's free cash flow more than triple

Tue, 08th Sep 2020 08:40

(Sharecast News) - Genus posted a big uplift in profits before tax with cash flows more than tripling thanks to strong sales in China.
For the year ending on 30 June, the cattle and swine genetics specialist a 13% jump in sales to reach £551.4m and a 22% rise in profits to £71.0m on adjusted basis, for a 23% improvement in earnings per share to 85.4p.

Free cash flow meanwhile was 352% higher to £35.2m.

The company's boss, Stehpen Wilson, highlighted the strong demand seen in China for its swine products, as large customers looked to restock their herds in the wake of the 2019 African Swine Fever epidemic.

Wilson also called attention to the operational challenges during the period for meat processors in the US due to the Covid-19 pandemic, anticipating that the sector would continue to be impacted during the 2021 financial with management anticipating greater currency headwinds.

The group's porcine genetics business, known as PIC, saw sales rise by 17%, with volumes up by 13% or 6% excluding China, and operating profits growing by 25%.

ABS, which is Genus's dairy and beef cattle arm, meanwhile saw volume growth of 8% with total revenues 9% higher.

Indeed, the firm more than doubled the size of its PIC supply chain in China to capitalise on the country's drive to restock.

Weaker currencies, mainly in Latin America, subtracted £3.4m from topline growth for the year.

comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency and quality, and our customers use them to supply the global dairy and meat supply chains.

Regarding the outlook, despite the likelihood that Covid-19 would continue to heavily impact "many sectors" across the globe for some time, Genus expected trading over the year ahead to be in line with management's expectations.

At period end, the group's net debt, including £24.7m resulting from the adoption of IFRS 16, stood at £102.6m and at 0.9 times the company's earnings before interest, taxes, depreciation and amortisation.

Genus bumped up its dividend payout by 5% to 29.1p.



More News
12 Aug 2016 07:06

Genus suffers legal setback Stateside

(ShareCast News) - Genus suffered a legal setback Stateside as a US judge handed down a series of verdicts against the animal genetics specialist. The US District Court for Wisconsin ruled that two of Genus rival ST´s patents were valid and had been infringed and that ABS, a unit of Genus, had mater

Read more
11 Aug 2016 10:01

Genus and Sexing still battling over semen

(ShareCast News) - Animal genetics company Genus announced the first jury verdicts in its antitrust litigation against Inguran, operating as Sexing Technologies, relating to ABS's 'Genus Sexed Semen' processing technology. The FTSE 250 firm said that at the trial in the US District Court for the Wes

Read more
11 Aug 2016 07:45

Genus Says US Court Finds Against Inguran But Sees No Injury To Genus

Read more
4 Aug 2016 11:59

Thursday broker round-up

(ShareCast News) - Next: Goldman Sachs reiterates sell with a target price of 4800p. Standard Chartered: JP Morgan maintains overweight with a 800p target. Shire: JP Morgan reiterates overweight with a 6300p target. Genus: HSBC stays at buy with a 2200p target. Nichols: UBS keeps at buy with a ta

Read more
4 Jul 2016 08:37

BROKER RATINGS SUMMARY: Liberum Downgrades Property Stocks

Read more
4 Jul 2016 08:21

CORRECT (01/07): WINNERS & LOSERS SUMMARY

Read more
1 Jul 2016 15:58

LONDON MARKET CLOSE: Stocks Close Week After Brexit Vote On A High

Read more
1 Jul 2016 11:09

LONDON MARKET MIDDAY: Carney Boosts Stocks As easyJet Eyes Own Brexit

Read more
1 Jul 2016 09:11

WINNERS & LOSERS SUMMARY: Dignity And Genus Benefit From Upgrades

Read more
1 Jul 2016 08:51

BROKER RATINGS SUMMARY: Berenberg - Buy Dignity; Liberum - Buy Genus

Read more
1 Jul 2016 07:24

LONDON BRIEFING: Carney Lifts Brexit Blues With Policy Assurance

Read more
20 Jun 2016 09:25

ITV, Wolseley are Liberum's top-picks in case of Bremain, Brexit

(ShareCast News) - Depending on whether the UK finally decided to 'Remain' or 'Leave' then different London-listed securities were likelier to 'outperform' their respective sectors, Liberum said. The broker's 'top-picks' under a 'Remain', 'Leave' and 'Either way' scenario were, ITV, Wolseley and Bal

Read more
26 May 2016 14:30

FTSE 250 movers: Ibstock retreats as Pets at Home accelerates

(ShareCast News) - The FTSE 250 slipped further into the red late as Thursday wore on, despite having peeped its head above water around midday. Leading the index lower, shares in Ibstock subsided as the brick maker reported a slow start to the year for its UK clay business had lasted four months b

Read more
18 May 2016 09:49

Genus announces collaboration with Caribou Biosciences

(ShareCast News) - Genus announced a strategic collaboration with US-based Caribou Biosciences that will give the London-listed animal genetics group exclusive license to Caribou's gene editing technology platform. Caribou's CRISPR-Cas9 technology accurately targets and cuts DNA to produce precise a

Read more
18 May 2016 07:01

Genus Signs Gene Editing Platform Deal With Caribou Biosciences

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.